Valuation : Charles River Laboratories International, Inc.

Market Cap 13.77B 11.85B 11.15B 10.19B 19.05B 1,300B 19.11B 132B 51.13B 667B 51.72B 50.59B 2,149B P/E 2026 *
77.2x
P/E 2027 * 33.1x
Enterprise Value 15.88B 13.67B 12.86B 11.75B 21.98B 1,500B 22.04B 152B 58.97B 769B 59.65B 58.35B 2,479B EV / Sales 2026 *
4.06x
EV / Sales 2027 * 3.85x
Free-Float
95.58%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Charles River Laboratories International, Inc.

1 day+0.11%
1 week-3.32%
Current month+1.07%
1 month+25.15%
1 week 231.36
Extreme 231.3635
234.24
1 month 210.07
Extreme 210.072
242.28
Current year 146.62
Extreme 146.619
242.28
1 year 146.62
Extreme 146.619
242.28
3 years 146.62
Extreme 146.619
242.28
5 years 146.62
Extreme 146.619
242.28
10 years 146.62
Extreme 146.619
242.28
Manager TitleAgeSince
Chief Executive Officer 56 04/05/2026
Director of Finance/CFO 58 05/04/2026
Chief Tech/Sci/R&D Officer 45 11/01/2026
Director TitleAgeSince
Chairman 75 31/12/1999
Director/Board Member 56 04/05/2026
Chairman 69 04/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
+0.11%-3.32% - - 14B
-2.54%-3.60%-0.60%+15.17% 50.35B
-0.40%+1.03%+439.20%+499.20% 45.2B
-1.42%+2.30%+45.46%+19.36% 44.71B
-1.22%-2.31%+12.40%+71.48% 41.24B
+0.53%-1.67%+15.16%+49.88% 33.08B
-0.21%+9.14% - - 17.81B
-0.35%-1.56%+22.59%+116.19% 16.56B
-1.01%+0.50%+15.83%+27.98% 14.82B
-1.65%-1.03%+77.75%+37.63% 14B
Average -0.82%+0.62%+78.48%+104.61% 30.86B
Weighted average by Cap. -0.99%+0.63%+94.49%+121.77%

Financials

2026 *2027 *
Net sales 3.91B 3.37B 3.17B 2.89B 5.41B 369B 5.43B 37.42B 14.52B 189B 14.69B 14.37B 610B 4B 3.44B 3.24B 2.96B 5.54B 378B 5.55B 38.28B 14.85B 194B 15.02B 14.7B 624B
Net income 162M 140M 131M 120M 225M 15.33B 225M 1.55B 603M 7.86B 610M 596M 25.34B 428M 368M 346M 316M 592M 40.38B 593M 4.09B 1.59B 20.72B 1.61B 1.57B 66.74B
Net Debt 2.11B 1.82B 1.71B 1.56B 2.92B 199B 2.93B 20.21B 7.84B 102B 7.93B 7.76B 330B 1.63B 1.4B 1.32B 1.21B 2.26B 154B 2.26B 15.6B 6.05B 78.99B 6.12B 5.99B 254B
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change
04/09/26 CHF 234.24 +0.11%
03/09/26 CHF 233.98 +0.82%
02/09/26 CHF 232.08 +0.31%
01/09/26 CHF 231.36 -0.17%
31/08/26 CHF 231.75 -2.23%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
288.50USD
Average target price
281.00USD
Spread / Average Target
-2.60%

Quarterly revenue - Rate of surprise